STIC-ILL RC 261.A1 A46

From: Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
   1993, 53(21):5300-5307
   1995 Jun 15, 55(12):2528-2532

2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13

3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191

4. Proc Amer Assoc Cancer Research, 1994, Vol. 35, page 60

5. Oncogene, 1994 May, 9(5):1461-1467

6. International Journal of Cancer:
   1995 Jan 3, 60(1):129-136
   1997 Jun 11, 71(6):1061-1065

7. Clinical Cancer Research, 1998 Mar, 4(3):791-797

8. Molecular biology of the Cell:
   Nov 1998, Vol. 9, suppl., page 134A
   Nov 1998, Vol. 9, suppl., page 773

9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

NO 615 448958

STIC-ILL

From: Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
   1993, 53(21):5300-5307
   1995 Jun 15, 55(12):2528-2532
2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13
3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191
4. Proc Amer Assoc Cancer Research, 1994 Vol. 35, page 60
5. Oncogene, 1994 May, 9(5):1461-1467
6. International Journal of Cancer:
   1995 Jan 3, 60(1):129-136
   1997 Jun 11, 71(6):1061-1065
7. Clinical Cancer Research, 1998 Mar, 4(3) 791-797
8. Molecular biology of the Cell:
   Nov 1998, Vol. 9, suppl., page 134A
   Nov 1998, Vol. 9, suppl., page 773
9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

1046-6673

CAS
6/5 ~~ISI~~ NO

CIST
6/6

RC 261.A1 C2
mic

STIC-ILL

From: Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
~~1993, 53(21):5300-5307~~
~~1995 Jun 15, 55(12):2528-2532~~

2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13

3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191

4. Proc Amer Assoc Cancer Research, 1994, Vol. 35, page 60

5. Oncogene, 1994 May, 9(5):1461-1467

6. International Journal of Cancer:
1995 Jan 3, 60(1):129-136
1997 Jun 11, 71(6):1061-1065

7. Clinical Cancer Research, 1998 Mar, 4(3):791-797

8. Molecular biology of the Cell:
Nov 1998, Vol. 9, suppl., page 134A
Nov 1998, Vol. 9, suppl., page 773

9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

RC261.A1C2

STIC-ILL

From: Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
   1993, 53(21):5300-5307
   1995 Jun 15, 55(12):2528-2532

2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13

3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191

4. Proc Amer Assoc Cancer Research, 1994, Vol. 35, page 60

5. Oncogene, 1994 May, 9(5):1461-1467

6. International Journal of Cancer:
   1995 Jan 3, 60(1):129-136
   1997 Jun 11, 71(6):1061-1065

7. Clinical Cancer Research, 1998 Mar, 4(3):791-797

8. Molecular biology of the Cell:
   Nov 1998, Vol. 9, suppl., page 134A
   Nov 1998, Vol. 9, suppl., page 773

9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

UPL

Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
   1993, 53(21):5300-5307
   1995 Jun 15, 55(12):2528-2532

2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13

3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191

4. Proc Amer Assoc Cancer Research, 1994, Vol. 35, page 60

5. Oncogene, 1994 May, 9(5):1461-1467

6. International Journal of Cancer:
   1995 Jan 3, 60(1):129-136
   ~~1997 Jun 11, 71(6):1061-1065~~

7. Clinical Cancer Research, 1998 Mar, 4(3):791-797

8. Molecular biology of the Cell:
   Nov 1998, Vol. 9, suppl., page 134A
   Nov 1998, Vol. 9, suppl., page 773

9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

QH 604 C442

From: Canella, Karen
Sent: Wednesday, June 04, 2003 9:35 PM
To: STIC-ILL
Subject: ill order 09/640,952

Art Unit 1642 Location 8E12(mail)

Telephone Number 308-8362

Application Number 09/640,952

1. Cancer Research:
   1993, 53(21):5300-5307
   1995 Jun 15, 55(12):2528-2532

2. Br J Cancer, 1993, Vol. 67, Supppl. XX, page 13

3. American Journal of clinical Pathology, 1984 Feb, 81(2):184-191

4. Proc Amer Assoc Cancer Research, 1994, Vol. 35, page 60

5. Oncogene, 1994 May, 9(5):1461-1467

6. International Journal of Cancer:
   1995 Jan 3, 60(1):129-136
   1997 Jun 11, 71(6):1061-1065

7. Clinical Cancer Research, 1998 Mar, 4(3):791-797

8. Molecular biology of the Cell:
   ~~Nov 1998, Vol. 9, suppl., page 134A~~ abstract
   ~~Nov 1998, Vol. 9, suppl., page 773~~

9. Journal of the american Society of Nephrology, 1998 Sep, Vol. 9 (Program and Abstract Issue), page 530A

```
      (FILE 'HOME' ENTERED AT 20:18:39 ON 04 JUN 2003)

      FILE 'MEDLINE, BIOSIS, SCISEARCH, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS'
      ENTERED AT 20:18:58 ON 04 JUN 2003
L1          6026 S EPH OR EPHA OR EPHA2 OR ECK
L2           153 S L1 AND METASTA?
L3            49 S L2 AND PY<2000
L4            17 DUP REM L3 (32 DUPLICATES REMOVED)
L5            22 S EPHA2(3A)ECK
L6             8 DUP REM L5 (14 DUPLICATES REMOVED)

      FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 20:34:03 ON 04 JUN 2003
L7             4 S EPH(W)A2
L8             4 DUP REM L7 (0 DUPLICATES REMOVED)

      FILE 'MEDLINE, BIOSIS, SCISEARCH, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS'
      ENTERED AT 20:35:14 ON 04 JUN 2003
L9            13 S EPH(W)A2
L10            5 DUP REM L9 (8 DUPLICATES REMOVED)

      FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 20:36:49 ON 04 JUN 2003
L11         4299 S EPH OR EPHA OR EPHA2 OR ECK
L12            4 S EPH(W)A2
L13           12 S EPHRIN(W)A1
L14         4304 S L11 OR L12 OR L13
L15           80 S L14(S)METASTA?
L16           35 S L15 AND PD<19990817
L17            4 S L15 AND (D7 OR B2D6)
```

```
     (FILE 'HOME' ENTERED AT 20:18:39 ON 04 JUN 2003)

     FILE 'MEDLINE, BIOSIS, SCISEARCH, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS'
     ENTERED AT 20:18:58 ON 04 JUN 2003
L1         6026 S EPH OR EPHA OR EPHA2 OR ECK
L2          153 S L1 AND METASTA?
L3           49 S L2 AND PY<2000
L4           17 DUP REM L3 (32 DUPLICATES REMOVED)
L5           22 S EPHA2(3A)ECK
L6            8 DUP REM L5 (14 DUPLICATES REMOVED)

     FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 20:34:03 ON 04 JUN 2003
L7            4 S EPH(W)A2
L8            4 DUP REM L7 (0 DUPLICATES REMOVED)

     FILE 'MEDLINE, BIOSIS, SCISEARCH, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS'
     ENTERED AT 20:35:14 ON 04 JUN 2003
L9           13 S EPH(W)A2
L10           5 DUP REM L9 (8 DUPLICATES REMOVED)

     FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 20:36:49 ON 04 JUN 2003
L11        4299 S EPH OR EPHA OR EPHA2 OR ECK
L12           4 S EPH(W)A2
L13          12 S EPHRIN(W)A1
L14        4304 S L11 OR L12 OR L13
L15          80 S L14(S)METASTA?
L16          35 S L15 AND PD<19990817
L17           4 S L15 AND (D7 OR B2D6)
L18          63 S L14 AND (D7 OR B2D6)
L19        2459 S L14 AND PD<19990817
L20          22 S L18 AND PD<19990817

     FILE 'STNGUIDE' ENTERED AT 20:58:52 ON 04 JUN 2003

     FILE 'PCTFULL, EUROPATFULL, USPATFULL' ENTERED AT 20:59:32 ON 04 JUN 2003

     FILE 'MEDLINE, BIOSIS, SCISEARCH, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS'
     ENTERED AT 21:04:39 ON 04 JUN 2003
L21         205 S EPHRINA1 OR (EPHRIN(W)A1) OR (EPHRINA(W)1)
L22          17 S L21(S)METASTA?
L23           5 S L22 AND PY<2000
L24           1 DUP REM L23 (4 DUPLICATES REMOVED)

     FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 21:07:37 ON 04 JUN 2003
L25         149 S L14/TI,AB
L26           3 S L25 AND (D7 OR B2D6)
L27           2 S L26 AND METASTA?
L28          17 S L25 AND METASTA?
L29           7 S L28 AND PD<19990817

=> s l25 and pd>20001129
L30          34 L25 AND PD>20001129

=> s l30 and ad<19990817
L31          10 L30 AND AD<19990817

=> s l31 not l29
```

L32 10 L31 NOT L29

L8 ANSWER 2 OF 2 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1984:268313 BIOSIS
DOCUMENT NUMBER: BA78:4793
TITLE: IMMUNO HISTOCHEMICAL LOCALIZATION OF EPIDERMAL AND MALLORY BODY CYTO KERATIN IN UNDIFFERENTIATED EPITHELIAL TUMORS COMPARISON WITH ULTRASTRUCTURAL FEATURES.
AUTHOR(S): KAHN H J; HUANG S-N; HANNA W M; BAUMAL R; PHILLIPS M J
CORPORATE SOURCE: DEP. PATHOL., HOSP. SICK CHILDREN, 555 UNIVERSITY AVE., TORONTO, ONTARIO, CANADA M5G 1X8.
SOURCE: AM J CLIN PATHOL, (1984) **81** (2), **184**-191.
CODEN: AJCPAI. ISSN: 0002-9173.
FILE SEGMENT: BA; OLD
LANGUAGE: English
AB Anaplastic tumors (21) were studied by light microscopy (LM), immunoperoxidase staining using anti-epidermal cytokeratin (**ECK**) and anti-Mallory body cytokeratin (MBCK) antibodies, and EM to determine whether an epithelial origin could be confirmed. The tumors were derived from [human] lung, stomach, colon, breast, uterus, kidney, bladder and mesothelium. By LM, the tumors consisted of either large and polygonal, spindle or small, round cells. With immunoperoxidase staining, 11 (52%) of the anaplastic tumors were positive for **ECK**, positivity being either absent or only weak in the main tumor mass, but marked in areas of infiltration and metastases. In contrast, all of the anaplastic tumors were positive for MBCK in the main tumor mass, infiltrating areas and metastases. In the case of adenocarcinomas, staining was either web-like or diffuse throughout the cytoplasm with concentration occurring at the cell surface, whereas in mesotheliomas, the staining was either diffuse or showed focal perinuclear accentuation. Twelve of 13 anaplastic tumors examined by EM showed epithelial features (desmosomes, tonofilaments, lumina and/or microvilli). As controls, 21 non-epithelial tumors (5 melanomas, 8 sarcomas and 8 lymphomas) showed no reactivity with either cytokeratin antibody. The epithelial nature of undifferentiated and poorly differentiated tumors can be confirmed by immunohistochemistry using anti-cytokeratin antibodies.